Last reviewed · How we verify

NCT03717896

Thiamine As Adjunctive Therapy for Diabetic Ketoacidosis

Completed Phase 2 Last updated 31 October 2024
What this trial tests

Phase 2 trial testing 200mg IV thiamine in 50mL 0.9% saline in Diabetic Ketoacidosis in 100 participants. Completed in 1 October 2024.

Timeline
21 November 2018
Primary endpoint
30 September 2024
1 October 2024

Quick facts

Lead sponsorBeth Israel Deaconess Medical Center
PhasePhase 2
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposetreatment
Enrollment100
Start date21 November 2018
Primary completion30 September 2024
Estimated completion1 October 2024
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Beth Israel Deaconess Medical Center

Who can join

18 and older, any sex, with Diabetic Ketoacidosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a randomized, double-blind, placebo-controlled trial to determine if administration of intravenous thiamine will lead to quicker resolution of acidosis in patients admitted to the hospital with diabetic ketoacidosis. The investigators will secondarily investigate whether thiamine improves cellular oxygen consumption, shortens intensive care unit (ICU) and hospital stay or decreases hospital resource utilization.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Thiamine as adjunctive therapy for diabetic ketoacidosis (DKAT) trial protocol and statistical analysis plan: a prospective, single-centre, double-blind, randomised, placebo-controlled clinical trial in the USA.
    Vine J, Mehta S, Balaji L, Berg KM, et al · · 2024 · cited 3× · PMID 38423765 · DOI 10.1136/bmjopen-2023-077586
  2. The Impact of Extended-Hours Patient Recruitment on Critical Care Clinical Trial Enrollment.
    Lee JH, Vine J, Meier M, Berkovitz A, et al · · 2025 · PMID 40138529 · DOI 10.1097/cce.0000000000001239
  3. Cellular oxygen consumption in patients with diabetic ketoacidosis.
    Vine J, Lee JH, Balaji L, Grossestreuer AV, et al · · 2024 · PMID 39497011 · DOI 10.1186/s40635-024-00673-0

Verify or expand the search:

Other recruiting trials for Diabetic Ketoacidosis

Currently open trials in the same condition.

Other Beth Israel Deaconess Medical Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03717896.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing